{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:16:17Z","timestamp":1792444577022,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"German Research Council","award":["HA 2393\/6-1"],"award-info":[{"award-number":["HA 2393\/6-1"]}]},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Charles and Ann Johnson Foundation"},{"name":"Austrian Science","award":["SFB F4704"],"award-info":[{"award-number":["SFB F4704"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jaci.2020.03.044","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T21:31:22Z","timestamp":1589146282000},"page":"356-366.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis"],"prefix":"10.1016","volume":"146","author":[{"given":"Karin","family":"Hartmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans D.","family":"Menssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Redhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2020.03.044_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000101711","article-title":"Mastocytosis: state of the art","volume":"74","author":"Horny","year":"2007","journal-title":"Pathobiology"},{"key":"10.1016\/j.jaci.2020.03.044_bib2","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.03.044_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.03.044_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2020.03.044_bib5","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/ajh.24553","article-title":"Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2020.03.044_bib6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaci.2020.03.044_bib7","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.03.044_bib8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2020.03.044_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000059404","article-title":"Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease","volume":"128","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2020.03.044_bib10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.03.044_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000048188","article-title":"Mastocytosis: mediator-related signs and symptoms","volume":"127","author":"Castells","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2020.03.044_bib12","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/all.12920","article-title":"Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis","volume":"71","author":"van Anrooij","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2020.03.044_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.03.044_bib14","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2020.03.044_bib15","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2020.03.044_bib16","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2020.03.044_bib17","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"61","article-title":"Mastocytosis","author":"Horny","year":"2017"},{"key":"10.1016\/j.jaci.2020.03.044_bib18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"key":"10.1016\/j.jaci.2020.03.044_bib19","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0959-8049(94)90182-1","article-title":"The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress","volume":"30A","author":"Portenoy","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaci.2020.03.044_bib20","series-title":"User's manual for the SF-12v2 Health Survey","author":"Ware","year":"2010"},{"key":"10.1016\/j.jaci.2020.03.044_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/14737167.4.2.171","article-title":"Memorial Symptom Assessment Scale","volume":"4","author":"Chang","year":"2004","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jaci.2020.03.044_bib22","doi-asserted-by":"crossref","first-page":"8269","DOI":"10.1200\/jco.2004.22.90140.8269","article-title":"Clinically significant differences (CSD) in the Memorial Symptom Assessment Scale Short Form (MSAS-SF) [abstract]","volume":"22","author":"Chang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2020.03.044_bib23","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/cncr.29415","article-title":"How much do cancer-related symptoms contribute to health-related quality of life in lung and colorectal cancer patients? A\u00a0report from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium","volume":"121","author":"Kenzik","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jaci.2020.03.044_bib24","first-page":"1089","article-title":"The persistence of symptom burden: symptom experience and quality of life of cancer patients across one year","volume":"22","author":"Deshields","year":"2014","journal-title":"Supp Care Cancer"},{"key":"10.1016\/j.jaci.2020.03.044_bib25","first-page":"1171","article-title":"Symptom prevalence, frequency, severity, and distress during chemotherapy for patients with colorectal cancer","volume":"22","author":"Pettersson","year":"2014","journal-title":"Supp Care Cancer"},{"key":"10.1016\/j.jaci.2020.03.044_bib26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2020.03.044_bib27","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.03.044_bib28","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2020.03.044_bib29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.12265","article-title":"Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study","volume":"161","author":"Gruson","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2020.03.044_bib30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.03.044_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaci.2020.03.044_bib32","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/all.12842","article-title":"Development and validation of the Mastocytosis Quality of Life questionnaire: MC-QoL","volume":"71","author":"Siebenhaar","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2020.03.044_bib33","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.03.044_bib34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0609.2010.01407.x","article-title":"A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions","volume":"84","author":"Pardanani","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaci.2020.03.044_bib35","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","article-title":"Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth","volume":"30","author":"Peter","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2020.03.044_bib36","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in indolent systemic mastocytosis patients: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.03.044_bib37","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of multikinase inhibitor midostaurin in patients with advanced systemic mastocytosis: long-term results for a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2020.03.044_bib38","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2020.03.044_bib39","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/cncr.29415","article-title":"How\u00a0much do cancer-related symptoms contribute to health-related quality of life in lung and colorectal cancer patients? A\u00a0report from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium","volume":"121","author":"Kenzik","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jaci.2020.03.044_bib40","series-title":"SF-12: How to Score the SF-12 Physical and Mental Health Summary Scales","author":"Ware","year":"1995"},{"key":"10.1016\/j.jaci.2020.03.044_bib41","first-page":"1089","article-title":"The persistence of symptom burden: symptom experience and quality of life of cancer patients across one year","volume":"22","author":"Deshields","year":"2014","journal-title":"Supp Care Cancer"},{"key":"10.1016\/j.jaci.2020.03.044_bib42","first-page":"1171","article-title":"Symptom prevalence, frequency, severity, and distress during chemotherapy for patients with colorectal cancer","volume":"22","author":"Pettersson","year":"2014","journal-title":"Supp Care Cancer"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674920306333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674920306333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:25:24Z","timestamp":1758792324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674920306333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0091674920306333"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2020.03.044","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2020.03.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}